Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WD 40 COWDFC · Entity 4262 | Director | December 12, 2025 | December 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WD 40 CO
Report date December 12, 2025 · Filed December 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,503 |
Reported balance
After 2025-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 612 · Balance 2,503 F1: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on June 16, 2025. This RSU award, which was granted effective December 12, 2025 and had an aggregate fair market value of approximately $125,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F2: Represents fully vested RSUs treated as common stock equivalents (adjusted downward by 7 due to last year's grant erroneously reported as 412 instead of 405). Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on June 16, 2025. This RSU award, which was granted effective December 12, 2025 and had an aggregate fair market value of approximately $125,000 on such date, is the non-elective portion of annual director compensation and vests upon grant.
F2: Represents fully vested RSUs treated as common stock equivalents (adjusted downward by 7 due to last year's grant erroneously reported as 412 instead of 405). Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MARRONE BIO INNOVATIONS INC
Report date July 12, 2022 · Filed July 14, 2022
Section 16 reporting ended · disclosed 2022-07-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-07-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-12 · Grant · Acquired 167,812 · Balance 167,812 F1: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). F2: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. Row 2 · 2022-07-12 · Disposition to issuer · Disposed 167,812 · Balance 0 F3: Disposed of pursuant to the Merger Agreement in exchange for 14,767 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-12 · Exercise / conversion · Disposed 167,812 · Balance 0 F2: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F4: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F5: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. |
Filing footnotes · ownership attribution and instrument terms
F1: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").
F2: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
F3: Disposed of pursuant to the Merger Agreement in exchange for 14,767 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F4: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
F5: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2025 Filed Dec 13, 2025 01:08 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105132-25-000122 · form4.xml · nonDerivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,503 F1 · shares: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on June 16, 2025. This RSU award, which was granted effective December 12, 2025 and had an aggregate fair market value of approximately $125,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F1 · price: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on June 16, 2025. This RSU award, which was granted effective December 12, 2025 and had an aggregate fair market value of approximately $125,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F2 · balance_after: Represents fully vested RSUs treated as common stock equivalents (adjusted downward by 7 due to last year's grant erroneously reported as 412 instead of 405). Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:16 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105132-24-000106 · form4.xml · nonDerivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,898 F2 · security: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. F1 · shares: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on October 3, 2024. This RSU award, which was granted effective December 12, 2024 and had an aggregate fair market value of approximately $110,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F1 · price: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with Issuer's Directors' Compensation Policy and Election Plan adopted on October 3, 2024. This RSU award, which was granted effective December 12, 2024 and had an aggregate fair market value of approximately $110,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F2 · balance_after: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 14:24 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 406 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105132-23-000101 · form4.xml · nonDerivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,486 F1 · security: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. F2 · shares: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with the Issuer's Directors' Compensation Policy and Election Plan adopted on October 5, 2023. This RSU award, which was granted effective December 12, 2023 and had an aggregate fair market value of approximately $97,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F2 · price: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with the Issuer's Directors' Compensation Policy and Election Plan adopted on October 5, 2023. This RSU award, which was granted effective December 12, 2023 and had an aggregate fair market value of approximately $97,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F1 · balance_after: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 00:30 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-021607 · doc1.xml · nonDerivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080 F1 · security: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. F2 · price: Represents a restricted stock unit ("RSU") award covering shares of Issuer's common stock granted in accordance with the Issuer's Directors' Compensation Policy and Election Plan adopted on October 12, 2021. This RSU award, which was granted effective December 13, 2022 and had an aggregate fair market value of approximately $80,000 on such date, is the non-elective portion of annual director compensation and vests upon grant. F1 · balance_after: Represents fully vested RSUs treated as common stock equivalents. Following termination of the Reporting Person's service as a director, the RSUs will be settled with Issuer's common stock. Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 20:36 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionRestricted Stock Units · Derivative | 167,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042203 · doc4.xml · derivative · entry 3 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F4 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · shares: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F5 · shares: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. F5 · derivative.exercise_date: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. F5 · derivative.expiration_date: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. F2 · derivative.underlying_shares: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F5 · derivative.underlying_shares: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 20:36 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Disposition to issuerCommon Stock | 167,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042203 · doc4.xml · nonDerivative · entry 2 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Disposed of pursuant to the Merger Agreement in exchange for 14,767 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 20:36 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantCommon Stock | 167,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042203 · doc4.xml · nonDerivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,812 F1 · shares: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). F2 · shares: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F1 · price: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 16:20 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-040654 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 10,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on June 30, 2022. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on June 30, 2022. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 16:06 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023839 · doc4.xml · derivative · entry 2 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F3 · derivative.exercise_date: Restricted stock units granted as compensation for serving on the board vest with respect to 100% of the total shares on April 6, 2023, with pro rata vesting based on days elapsed since grant in event of a change in control event prior to that date. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F3 · derivative.expiration_date: Restricted stock units granted as compensation for serving on the board vest with respect to 100% of the total shares on April 6, 2023, with pro rata vesting based on days elapsed since grant in event of a change in control event prior to that date. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 16:06 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023839 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 10,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: Restricted stock units granted as compensation for serving on committees vest with respect to 100% of the total shares subject to the grant on April 6, 2022. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: Restricted stock units granted as compensation for serving on committees vest with respect to 100% of the total shares subject to the grant on April 6, 2022. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:12 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-000685 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 10,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on December 31, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on December 31, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 01:06 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-022123 · doc1.xml · nonDerivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · shares: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for a non-elective portion of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F1 · price: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for a non-elective portion of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F2 · balance_after: Total represents 600 Restricted Stock Units (Common Stock equivalents). Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 17:31 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059086 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 10,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on September 30, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on September 30, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| June 30, 2021 Filed Jul 6, 2021 16:46 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045518 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 10,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on June 30, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on June 30, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| May 26, 2021 Filed May 28, 2021 17:41 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 17,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036601 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,076 Underlying: Common Stock · 17,076 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on May 26, 2022. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on May 26, 2022. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 18:39 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024795 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 10,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on March 31, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on March 31, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 17:06 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 6,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-000342 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,929 Underlying: Common Stock · 6,929 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on December 31, 2020. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on December 31, 2020. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 17:44 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 12,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056958 · doc4.xml · derivative · entry 2 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,432 Underlying: Common Stock · 12,432 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on May 31, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F3 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on May 31, 2021. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 17:44 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 42,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056958 · doc4.xml · derivative · entry 1 Lee Lara L · CIK 0001830288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,625 Underlying: Common Stock · 42,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vested with respect to 1/3rd of the total shares on the first anniversary of the vesting commencement date of November 2, 2020, and with respect to 1/24th of the remaining shares subject to the grant monthly thereafter for 24 months. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vested with respect to 1/3rd of the total shares on the first anniversary of the vesting commencement date of November 2, 2020, and with respect to 1/24th of the remaining shares subject to the grant monthly thereafter for 24 months. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.